medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2019, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2019; 35 (3)

SMILE in relapsed extranodal NK / T cell lymphoma

Martínez ADR, Gracia ME, Martínez ELY, Medina PVM, Mir EYL

Language: Spanish
References: 27
Page: 1-11
PDF size: 316.32 Kb.


ABSTRACT

Introduction: Extranodal lymphoma of NK/T cells, nasal type is an aggressive variety that occurs most frequently in East Asia and Latin America. The SMILE treatment regimen, based on dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide, showed adequate objective response rates in phase 1/2 studies. Objective: to present the first report of the application of the SMILE protocol in Cuba. Case presentation: 47-year-old white patient who presented early relapse of extranodal lymphoma of nasal NK/T cells in soft parts of the left anterior wall of the thorax. He received SMILE chemotherapy for 4 cycles and the evaluation at the end of the treatment showed that there was a complete response of the disease.


REFERENCES

  1. Haverkos BM, Pan Z, Gru AA, Freud AG, Rabinovitch R, Xu-Welliver M. Extranodal NK/T-cell lymphoma, nasal type (ENKTL-NT): An update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016; 11(6): 514–27. DOI:10.1007/s11899-016-0355-9.

  2. Suzuki R. Pathogenesis and Treatment of Extranodal Natural Killer/T-Cell Lymphoma. SeminHematol.2014; 51: 42-51.

  3. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for a dvanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016-20.

  4. Weiben Y, Wen Z, Yuntao Z, Jun Z,Yan W, Deliang Z, et al. L-asparaginase based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol.2003;78(2):163-7.

  5. Imashuku S1, Hibi S, Ohara T, Iwai A, Sako M, Kato M, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immune chemotherapy. HistiocyteSociety.Blood.1999;93(6):1869-74.

  6. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J ClinOncol.2011;29(33):4410-6.

  7. George LC1, Rowe M, Fox CP. Epstein-Barr virus and the pathogenesis of T and NK lymphoma: a mystery unsolved. Curr Hematol Malig Rep. 2012;7(4):276-84.

  8. Lanier L, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med. 1989; 169(6):2233-8.

  9. Tse E, Kwong YL. How I treat NK/T-cell lymphomas. Blood. 2013; 121(25): 4997-5005.

  10. Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8+ T cells. Nat Rev Immunol. 2011;11(10):645–57.

  11. Montaldo E, Vacca P, Moretta L, Mingari MC. Development of human natural killer cells and other innate lymphoid cells. Semin Immunol. 2014; 26(2):107–13.

  12. Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. Expert Rev Hematol. 2016;9(9):861–71.

  13. Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol.2014; 164:536–45.

  14. Karkera AC, Parsons BM, Borgert A, Go RS. NK/T cell lymphoma in the U.S: A population-based study using the National Cancer Database from 1998–2012. J Clin Oncol. 2016; 34(15 Supl):e19038.

  15. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F,et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (Aspa-Met-Dexregimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood.2011;117:1834–9.

  16. Kreisel FH. Hematolymphoid Lesions of the Sinonasal Tract. Head Neck Pathol. 2016;10:109–17.

  17. Kidwai SM, Parasher AK, Lin FY. An unusual presentation of NK/T-cell lymphoma, nasal-type in the United States. Am J Otolaryngol.2015;36:80–3.

  18. Qi S, Yahalom J, Hsu M, Chelius M, Lunning M, Moskowitz A, et al. Encouraging experience in the treatment of nasal type extra-nodal NK/T-cell lymphoma in a non-Asian population. Leuk Lymphoma. 2016 Nov;57(11):2575-83. doi: 10.1080/10428194.2016.1180689.

  19. Lima, M. Aggressive mature natural killer cell neoplasms: from epidemiology to diagnosis. Orphanet J Rare Dis 2013; 8: 95.doi: 10.1186/1750-1172-8-95.

  20. Yang Y, Zhu Y, Cao JZ, Zhang YJ, Xu LM, Yuan ZY, et al. Risk-adapted therapy for early-stage extranodal nasal-type NK/T-cell lymphoma: analysis from a multicenter study. Blood.2015; 126:1424–32.quiz 1517.

  21. Liu QF, Wang WH, Wang SL, Liu YP, Huang WT, Lu N, et al. Immunophenotypic and clinical differences between the nasal and extranasal subtypes of upper aerodigestive tract natural killer/T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2014;88(4):806-13.

  22. Vazquez A, Khan MN, Blake DM, Sanghvi S, Baredes S, Eloy JA. Extranodal natural killer/T-cell lymphoma: a population-based comparison of sinonasal and extranasal disease. Laryngoscope. 2014;124(4):888-95.

  23. Deng T, Zhang C, Zhang X, Wu S, Xu Y, Liu S, et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in IE/IIE extranodal nasal type natural killer/T cell lymphoma: a meta-analysis. PLoSOne. 2014;9(9):e106577.

  24. MatsumotoY, Nomura K, Kanda-Akano Y, Fujita Y, Nakao M, Ueda K, et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma. 2003;44:879–82.

  25. Jaccard A, Petit B,GiraultS, Suarez F, GressinR, Zini JM,et al. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol. 2009 Jan;20(1):110-6. DOI: 10.1093/annonc/mdn542.

  26. Lam Kwong Y, Seog Kim W, ThyeLim S, Jin Kim S, Tang T, Tse E, et al. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group Blood.2012;120:2973-80. DOI: 10.1182/blood-2012-05-431460

  27. Suzuki R. Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Sem Hematol. 2014;51:42–51.




2020     |     www.medigraphic.com